Scarica l'app Stockscreener
4.2326
15.09%
-0.7374
Precedente Chiudi:
$4.97
Aprire:
$4.36
Volume 24 ore:
1.95M
Relative Volume:
1.71
Capitalizzazione di mercato:
$336.50M
Reddito:
$129.42M
Utile/perdita netta:
$17.38M
Rapporto P/E:
20.72
EPS:
0.2043
Flusso di cassa netto:
$13.15M
1 W Prestazione:
-10.78%
1M Prestazione:
-5.59%
6M Prestazione:
-38.30%
1 anno Prestazione:
-50.06%
Intervallo 1D:
$4.038
$4.3876
Intervallo di 1 settimana:
$4.038
$5.1214
Portata 52W:
$4.038
$14.69
Niagen Bioscience Inc Stock (NAGE) Company Profile
Nome
Niagen Bioscience Inc
Settore
Industria
Telefono
310-388-6706
Indirizzo
10900 WILSHIRE BLVD, LOS ANGELES
Compare NAGE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
4.225 | 395.83M | 129.42M | 17.38M | 13.15M | 0.2043 |
VRTX
Vertex Pharmaceuticals Inc
|
426.27 | 108.54B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
710.26 | 75.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.09 | 50.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.91 | 40.45B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.66 | 32.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-27 | Iniziato | Canaccord Genuity | Buy |
| 2022-08-16 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-08-11 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2022-03-08 | Iniziato | ROTH Capital | Buy |
| 2019-10-16 | Iniziato | Oppenheimer | Outperform |
| 2019-02-14 | Iniziato | B. Riley FBR | Buy |
| 2017-11-27 | Ripresa | H.C. Wainwright | Buy |
| 2017-09-25 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-01-03 | Iniziato | Rodman & Renshaw | Buy |
Mostra tutto
Niagen Bioscience Inc Borsa (NAGE) Ultime notizie
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results - BioSpace
Niagen Bioscience Keeps Full-Year Sales Forecast Intact As Q1 Revenue, Profit Climbs (UPDATED) - Benzinga
Niagen Bioscience reaffirms 10%-15% 2026 growth outlook while increasing marketing spend expectations - MSN
Niagen Bioscience Earnings Call Highlights Growth Push - TipRanks
Niagen Bioscience Q1 2026 slides: e-commerce surges 14% amid transition - Investing.com
Niagen Bioscience (NAGE) Q1 Earnings and Revenues Top Estimates - Yahoo Finance
Niagen Bioscience Reports Q1 Results, Updates 2026 Outlook - TipRanks
Niagen (NAGE) Q1 2026 Earnings Call Transcript - AOL.com
Earnings call transcript: Niagen Bioscience Q1 2026 sees growth in e-commerce - Investing.com
Niagen Bioscience (NASDAQ:NAGE) Shares Slide After Q1 Earnings Miss and Spending Guidance - ChartMill
Niagen Bioscience: Q1 Earnings Snapshot - marketscreener.com
[8-K] Niagen Bioscience, Inc. Reports Material Event - Stock Titan
Segment sale lifts Niagen Bioscience (Nasdaq: NAGE) Q1 2026 profit - Stock Titan
Niagen Bioscience Is Maintained at Buy by Canaccord Genuity - Moomoo
CCORF Maintains Niagen Bioscience(NAGE.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Niagen Bioscience Inc expected to post earnings of 8 cents a shareEarnings Preview - TradingView
Niagen Bioscience (NAGE) Launches Telehealth Platform for Home D - GuruFocus
Niagen Bioscience launches telehealth platform with at-home kit - Investing.com UK
Niagen Bioscience Enters Telehealth With At-Home NAD+ Precursor Injection Kits - Athletech News
Niagen Bioscience launches telehealth platform with at-home kit By Investing.com - Investing.com India
Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering - 巴士的報
NAGE Technical Analysis | Trend, Signals & Chart Patterns | NIAGEN BIOSCIENCE INC (NASDAQ:NAGE) - ChartMill
Niagen Bioscience (NAGE) outlines 2026 director elections, auditor ratification and executive pay vote - Stock Titan
Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus - BioSpace
Insider Decision Unfolding At Niagen Bioscience: Robert Fried Exercises Options, Resulting In $46K - Benzinga
Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™ - Yahoo Finance
Insider Decision Unfolding At Niagen Bioscience: CEO Robert Fried Exercises Options(CORRECTED) - Benzinga
Notable Insider Move: Robert Fried Takes Part In Options Exercise At Niagen Bioscience, Resulting In $45K - Benzinga
Niagen Bioscience (NAGE) CEO adds 20,000 shares via option exercise - Stock Titan
Wall Street Zen Downgrades Niagen Bioscience (NASDAQ:NAGE) to Hold - MarketBeat
Niagen Bioscience Secures USP Monograph and Extends NR Patent Protection - HarianBasis.co
NAGE (Niagen Bioscience Inc.) reports solid Q4 2025 EPS beat and nearly 30 percent year over year revenue growth, stock rises modestly.Investment Community Signals - Cổng thông tin điện tử tỉnh Lào Cai
Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026 - BioSpace
Niagen Bioscience (NAGE) Well-Positioned With Recent Dietary Supplement Ingredient Monograph - Yahoo Finance
Niagen Bioscience (NAGE) price target decreased by 13.92% to 13.87 - MSN
Is Niagen Bioscience (NAGE) stock losing bullish momentum | Q4 2025: EPS Exceeds ExpectationsCommunity Buy Signals - Cổng thông tin điện tử Tỉnh Sơn La
How The Niagen Bioscience (NAGE) Story Is Shifting With New Q4 Models And Injectables - Yahoo Finance
Niagen Bioscience Stock Short Interest Report | NASDAQ:NAGE - Benzinga
Is Niagen Bioscience (NAGE) stock holding under pressure (Near Lows) 2026-04-20Social Momentum Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Niagen Bioscience, Inc. (NAGE) Stock Analysis: Unveiling a Potential 187.53% Upside in the Biotechnology Sector - DirectorsTalk Interviews
Niagen Bioscience And 2 Additional Promising Penny Stocks For Your Consideration - Sahm
NAGE Stock Price, Quote & Chart | NIAGEN BIOSCIENCE INC (NASDAQ:NAGE) - ChartMill
Niagen Bioscience: How Its Shift To Telehealth Makes It A Strong Buy (NASDAQ:NAGE) - Seeking Alpha
Niagen: High-Quality Growth At A Fair Price (NASDAQ:NAGE) - Seeking Alpha
Value Recap: Will Niagen Bioscience Inc stock go up in YEAR2026 Setups & Free High Return Stock Watch Alerts - baoquankhu1.vn
Q3 2025 Niagen Bioscience Inc Earnings Call Transcript - GuruFocus
Niagen Bioscience Inc Azioni (NAGE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Niagen Bioscience Inc Azioni (NAGE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Pamir Ozan | Chief Financial Officer |
Nov 14 '25 |
Buy |
6.81 |
4,465 |
30,406 |
7,372 |
| Pamir Ozan | Chief Financial Officer |
Nov 14 '25 |
Buy |
6.85 |
2,220 |
15,210 |
2,220 |
5.78%
0.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):